secwatch.observer — SEC 8-K summary
======================================

Issuer:     IGM Biosciences, Inc. (—)
CIK:        0001496323
Form:       8-K
Filed at:   2023-12-08T23:59:59+00:00
Accession:  0000950170-23-069045
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IGM Biosciences halts hematologic oncology programs, cuts workforce 22%, extends cash runway to Q2 2026
--------------------------------------------------------------------------------

- Reduces workforce by ~22%; focusing on DR5 agonist in colorectal cancer and T cell engagers in autoimmune diseases.
- Halts all hematologic oncology clinical development and targeted cytokine program; continues Sanofi collaboration.
- Plans to file IND for IGM-2644 (CD38 x CD3) for autoimmune disease in 2024.
- Cash runway now expected into Q2 2026; estimates $1.9M in employee-related restructuring charges.
- Enrollment continues in randomized aplitabart colorectal cancer trial (goal ~110 patients by Q1 2024).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1496323/000095017023069045/0000950170-23-069045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1496323/000095017023069045/igms-20231205.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-069045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer